Coya Therapeutics, Inc. (COYA) Stock Score, Valuation & Financial Research
Coya Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 37/100.
Quick answer for COYA
Coya Therapeutics, Inc. currently has a Wall Street Score of 37/100. The stored market price is $4.46. Its financial score is 46/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Coya Therapeutics, Inc. does
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to dim
COYA financial snapshot
- Wall Street Score:
- 37/100
- Current price:
- $4.46
- Market capitalization:
- $104.6M
- Revenue:
- $8.0M
- Net income:
- $-21.7M
- Free cash flow:
- $-10.7M
- Cash:
- $43.18B
- Total debt:
- $0
- EPS:
- -1.07
- Financial score:
- 46/100
- Valuation score:
- 0/100
- Revenue score:
- 14/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-10.7M, showing cash burn in the current stored period.
- The balance sheet shows $43.18B of cash versus $0 of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 46/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research COYA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.